These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
218 related items for PubMed ID: 15152748
1. Pharmacoeconomics of atrial fibrillation and stroke prevention. Bushnell CD, Matchar DB. Am J Manag Care; 2004 Apr; 10(3 Suppl):S66-71. PubMed ID: 15152748 [Abstract] [Full Text] [Related]
2. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. ROCKET AF Study InvestigatorsDuke Clinical Research Institute, Durham, NC, USA.. Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293 [Abstract] [Full Text] [Related]
3. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Am Heart J; 2009 Jun; 157(6):1064-73. PubMed ID: 19464418 [Abstract] [Full Text] [Related]
4. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, Koton S, Grossman E, Tanne D. Am J Cardiol; 2010 Feb 01; 105(3):411-6. PubMed ID: 20102959 [Abstract] [Full Text] [Related]
5. Atrial fibrillation and anticoagulation. Garnier LF, Rouesnel P, Espitalier F. Arch Mal Coeur Vaiss; 2004 Oct 01; 97(10):1001-5. PubMed ID: 16008178 [Abstract] [Full Text] [Related]
6. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators. Am Heart J; 2006 Nov 01; 152(5):967-73. PubMed ID: 17070169 [Abstract] [Full Text] [Related]
7. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Am J Kidney Dis; 2007 Sep 01; 50(3):421-32. PubMed ID: 17720521 [Abstract] [Full Text] [Related]
8. Role of new drugs for management of atrial fibrillation. Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM. Ann Pharmacother; 2012 Dec 01; 46(12):1656-70. PubMed ID: 23249869 [Abstract] [Full Text] [Related]
9. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Am J Geriatr Pharmacother; 2009 Jun 01; 7(3):159-66. PubMed ID: 19616184 [Abstract] [Full Text] [Related]
10. Anticoagulation in atrial fibrillation. Anderson M, Kirk M. Med Health R I; 2004 Apr 01; 87(4):98-100. PubMed ID: 15168633 [Abstract] [Full Text] [Related]
11. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Savelieva I, Bajpai A, Camm AJ. Ann Med; 2007 Apr 01; 39(5):371-91. PubMed ID: 17701479 [Abstract] [Full Text] [Related]
12. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Am J Cardiol; 2012 Sep 15; 110(6):845-51. PubMed ID: 22651881 [Abstract] [Full Text] [Related]
13. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Leey JA, McCabe S, Koch JA, Miles TP. Am J Geriatr Pharmacother; 2009 Aug 15; 7(4):197-203. PubMed ID: 19766951 [Abstract] [Full Text] [Related]
14. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. von Schéele B, Fernandez M, Hogue SL, Kwong WJ. Ann Pharmacother; 2013 May 15; 47(5):671-85. PubMed ID: 23606551 [Abstract] [Full Text] [Related]
15. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):472-9. PubMed ID: 22740012 [Abstract] [Full Text] [Related]
16. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L, ARISTOTLE Investigators. Am Heart J; 2010 Mar 01; 159(3):331-9. PubMed ID: 20211292 [Abstract] [Full Text] [Related]
17. Anticoagulant management in patients with atrial fibrillation. Fitzmaurice DA, Hobbs FD. Semin Thromb Hemost; 2009 Sep 01; 35(6):543-7. PubMed ID: 19787557 [Abstract] [Full Text] [Related]
18. Role of anticoagulant therapy in atrial fibrillation. Kottkamp H, Hindricks G, Breithardt G. J Cardiovasc Electrophysiol; 1998 Aug 01; 9(8 Suppl):S86-96. PubMed ID: 9727682 [Abstract] [Full Text] [Related]
19. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Clin Ther; 2008 Sep 01; 30(9):1726-36. PubMed ID: 18840379 [Abstract] [Full Text] [Related]
20. [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. Tomita F, Kohya T, Kitabatake A. Nihon Rinsho; 2000 Jun 01; 58(6):1326-34. PubMed ID: 10879060 [Abstract] [Full Text] [Related] Page: [Next] [New Search]